@article{6c23488cc6ea45cca53f3bf5c9191497,
title = "Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises",
abstract = "The efficacy of poly(ADP-ribose) polymerase inhibitors (PARPi) is restricted by inevitable drug resistance, while their use in combination with chemotherapy and targeted agents is commonly associated with dose-limiting toxicities. Immune checkpoint blockade (ICB) has demonstrated durable responses in different solid tumors and is well-established across multiple cancers. Despite this, single agent activity is limited to a minority of patients and drug resistance remains an issue. Building on the monotherapy success of both drug classes, combining PARPi with ICB may be a safe and well-tolerated strategy with the potential to improve survival outcomes. In this review, we present the preclinical, translational, and clinical data supporting the combination of DNA damage response (DDR) and ICB as well as consider important questions to be addressed with future research.",
keywords = "DNA damage response, PARP inhibitor, immune checkpoint inhibitor, immunotherapy",
author = "Pham, {Melissa M.} and Ngoi, {Natalie Y.L.} and Guang Peng and Tan, {David S.P.} and Yap, {Timothy A.}",
note = "Funding Information: M.M.P. is supported by the National Institutes of Health ( T32 CA101642/CA/NCI NIH HHS/United States). N.Y.L.N. is supported by the National Medical Research Council , Singapore ( MOH-FLWSHP19may-0006 ). D.S.P. T. is supported by the National Medical Research Council , Singapore ( CSAINV16may008 ), and has received charitable research funding from the Pangestu Family Foundation Gynaecological Cancer Research Fund . G.P. is supported by MD Anderson Cancer Center Support grant ( NCI CA016672 ), the Specialized Programs of Research Excellence grant from the National Cancer Institute ( 1P50CA217685-02 ), the U.S. Department of Defense Research Program ( OC140431 ), and the National Institutes of Health ( R01 CA181663 ). T.A.Y. is supported by MD Anderson Cancer Center Support grant ( NIH/NCI P30 CA016672 ), the U.S. Department of Defense Ovarian Cancer Research Program ( OC200482 ), and the V Foundation Clinical Scholar Program ( VC2020-001 ). Funding Information: M.M.P. is supported by the National Institutes of Health (T32 CA101642/CA/NCI NIH HHS/United States). N.Y.L.N. is supported by the National Medical Research Council, Singapore (MOH-FLWSHP19may-0006). D.S.P. T. is supported by the National Medical Research Council, Singapore (CSAINV16may008), and has received charitable research funding from the Pangestu Family Foundation Gynaecological Cancer Research Fund. G.P. is supported by MD Anderson Cancer Center Support grant (NCI CA016672), the Specialized Programs of Research Excellence grant from the National Cancer Institute (1P50CA217685-02), the U.S. Department of Defense Research Program (OC140431), and the National Institutes of Health (R01 CA181663). T.A.Y. is supported by MD Anderson Cancer Center Support grant (NIH/NCI P30 CA016672), the U.S. Department of Defense Ovarian Cancer Research Program (OC200482), and the V Foundation Clinical Scholar Program (VC2020-001). N.Y.L.N. received honoraria from AstraZeneca and Janssen. D.S.P.T. received research funding from AstraZeneca, Bayer, and Karyopharm and honoraria from AstraZeneca, MSD, Tessa Therapeutics, Novartis, Bayer, and Genmab. T.A.Y. received research funding (paid to his institution) from Artios, AstraZeneca, Bayer, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Merck, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, and Vertex Pharmaceuticals. In addition, he has reeived fees for consulting with Almac, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Bristol Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Jansen, Merck, Pfizer, Repare, Roche, Rubius, Schrodinger, Seattle Genetics, Varian, and Zai Labs. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2021",
month = oct,
doi = "10.1016/j.trecan.2021.05.004",
language = "English (US)",
volume = "7",
pages = "958--970",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
number = "10",
}